Australia's Therapeutic Goods Administration has given up the idea of adopting the US approach of requiring sponsors to add four-digit suffixes to the non-proprietary name of biological medicines to support their unique identification. The agency is concerned that the US approach may result in unnecessary regulatory burden for sponsors and could also cause confusion.
Following an extensive consultation with stakeholders, the TGA is not making any changes to its current naming convention...